Table 1 Demographics and vaccination-related adverse events

From: A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain

Participants, N

38

Age, mean (SD)

27.63(6.70)

Sex, male (%)

18 (47.4)

Adverse events, N (%)

7(18.4)

Injection site symptoms

Pruritus, N (%)

2(5.3)

Swollen, N (%)

1(2.6)

Systematic symptoms

Rash, N (%)

1(2.6)

Dizziness, N (%)

2(5.3)

Nausea, N (%)

1(2.6)

Fatigue, N (%)

1(2.6)

Back to article page